Compare Marathon Digital Holdings Inc (MARA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Marathon Digital Holdings Inc trades at $8.1 (market cap $3.52B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Marathon Digital Holdings Inc is far larger — about 3.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Digital Holdings Inc for 22 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MARA | MRVI | |
|---|---|---|
Market Cap | $3.52B | $972.90M |
Volume | 36,018,511 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $22.84 | $9.00 |
52-Week Low | $6.73 | $2.83 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $5.56B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Digital Holdings (MARA) trades at $9.11, down 3.5% on the day, reflecting ongoing volatility amid mixed technical signals. The stock shows bearish momentum in moving averages but bullish oscillators, with key resistance at $10. Fundamentally, the company reported significant losses with a net income margin of -429.71% in 2026, though valuation ratios appear attractive with P/E of 3.37. Recent news highlights continued analyst coverage and Bitcoin-related sector movements influencing stock performance.
MARA presents a high-risk opportunity with analyst consensus price target of $13 offering 43% upside potential, balanced by 45% buy and 45% hold ratings. However, persistent negative earnings, cash flow challenges, and Bitcoin market dependency create substantial risk. Investors must weigh the discounted valuation against the company's inability to achieve profitability despite revenue generation.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
